<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Thalidomide has been identified and its anti-inflammatory and immunomodulatory properties clarified </plain></SENT>
<SENT sid="1" pm="."><plain>This report expands our report of 2 entero-<z:chebi fb="6" ids="22696">Beh</z:chebi>çet disease children who developed significant steroid toxicity and improved dramatically with thalidomide </plain></SENT>
<SENT sid="2" pm="."><plain>Methods: We studied the effects of thalidomide in 7 <z:hpo ids='HP_0003621'>juvenile-onset</z:hpo> patients with severe, recurrent intestinal involvement of <z:chebi fb="6" ids="22696">Beh</z:chebi>çet disease </plain></SENT>
<SENT sid="3" pm="."><plain>Thalidomide was given at an initial dose of 2 mg/kg per day, and the dose was increased to 3 mg/kg per day if necessary (3 of 7 patients) or decreased to 1-0.5 mg/kg per day according to the responses to the drug </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: <z:hpo ids='HP_0000001'>All</z:hpo> 7 patients showed dramatic improvement in clinical symptoms with thalidomide therapy, and they successfully discontinued steroid therapy </plain></SENT>
<SENT sid="5" pm="."><plain>Patients receiving thalidomide were monitored for prolonged neurotoxicity, and the treatment and a few side effects were well tolerated by <z:hpo ids='HP_0000001'>all</z:hpo> patients </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSIONS: Our results indicate that thalidomide can be an efficacious medication in appropriately selected patients with some <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel diseases</z:e> with many chances of success </plain></SENT>
</text></document>